Guidelines for the management of chronic hepatitis C in patients infected after substance use.
Robaeys
G
G
Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Schiepse Bos, 6, B-3600 Genk, Belgium. geert.robaeys@zol.be
Buntinx
F
F
Bottieau
E
E
Bourgeois
S
S
Brenard
R
R
Colle
I
I
De Bie
J
J
Matheï
C
C
Mulkay
J P
JP
Van Damme
P
P
Van Ranst
M
M
Verrando
R
R
Michielsen
P
P
Bourgeois
N
N
Brenard
R
R
de Galocsy
Ch
Ch
Delwaide
J
J
Henrion
J
J
Horsmans
Y
Y
Michielsen
P
P
Reynaert
H
H
Robaeys
G
G
Sprengers
D
D
D000931:Antidotes / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001521:Behavior Therapy; D001530:Belgium / Q000453:epidemiology; D003131:Combined Modality Therapy; D015897:Comorbidity; D019317:Evidence-Based Medicine; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D006801:Humans; D008297:Male; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D016896:Treatment Outcome
D000931:Antidotes; D000998:Antiviral Agents